Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease

Executive Summary

Germany’s leading pharmaceutical company Bayer has taken future competition into account when stopping the Phase III development of finerenone for congestive heart failure, and targeting specific CHF patients for treatment with another potential cardiovascular, vericiguat.

You may also be interested in...



Changes Brewing At Bayer, But Pharma Strategy Remains On Point

Bayer AG is pursuing an acquisition of seed manufacturer Monsanto Co. that would establish agriculture as the largest business unit within the diversified life sciences company, usurping pharmaceuticals as the top revenue generator. Bayer Head of Innovation Kemal Malik said the company’s commitment to pharmaceuticals remains unwavering despite the M&A play.

Bayer Wary Of Future Competition In Renal Anemia Market

The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.

Bayer Chief Dekkers Departs With Words Of Warning, Wisdom For Pharma

Bayer AG, which is embarking on a new journey as a "pure" life science business with a fresh captain ready to take the helm for fiscal 2016, kept its focus on innovation during its annual results presentation in Leverkusen, Germany. But departing chief Dr. Marijn Dekkers had a few concerns to share with the wider industry before he grabs his coat.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel